Global Information
회사소개 | 문의 | 비교리스트

급성 회백수염 : 파이프라인 리뷰

Poliomyelitis (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 12월 상품코드 362372
페이지 정보 영문 104 Pages 배송안내
가격
US $ 2,000 ₩ 2,543,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,086,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,630,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


급성 회백수염 : 파이프라인 리뷰 Poliomyelitis (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 12월 페이지 정보 : 영문 104 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

급성 회백수염(Poliomyelitis) 치료제 개발 상황에 대해 조사했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 및 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스 및 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

급성 회백수염 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

급성 회백수염 : 기업에서 개발중인 치료제

급성 회백수염 : 대학/기관에서 연구중인 치료제

급성 회백수염 : 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

급성 회백수염 : 기업에서 개발중인 제품

급성 회백수염 : 대학/기관에서 연구중인 제품

급성 회백수염 치료제 개발에 참여하고 있는 기업

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • Bharat Biotech International Limited
  • Bilthoven Biologicals B.V.
  • Biological E. Limited
  • Boryung Pharmaceutical Co., Ltd.
  • Codagenix, Inc.
  • Daiichi Sankyo Company, Limited
  • Grifols, S.A.
  • Johnson & Johnson
  • LG Life Science LTD.
  • Nanolek, LLC
  • Panacea Biotec Limited
  • Sanofi Pasteur SA
  • Sentinext Therapeutics Sdn Bhd
  • Sinovac Biotech Ltd.
  • Taiga Biotechnologies, Inc.

급성 회백수염 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 투여 경로별
  • 분자 종류별

약제 개요

급성 회백수염 : 최근의 파이프라인 동향

급성 회백수염 : 휴지중인 프로젝트

급성 회백수염 : 개발이 중지된 제품

급성 회백수염 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSM 16.08.01

List of Tables

List of Tables

  • Number of Products under Development for Poliomyelitis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021
  • Poliomyelitis - Pipeline by Beijing Tiantan Biological Products Co Ltd, 2021
  • Poliomyelitis - Pipeline by Bharat Biotech Ltd, 2021
  • Poliomyelitis - Pipeline by Biken Co Ltd, 2021
  • Poliomyelitis - Pipeline by Biological E Ltd, 2021
  • Poliomyelitis - Pipeline by Biological Mimetics Inc, 2021
  • Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, 2021
  • Poliomyelitis - Pipeline by CanSino Biologics Inc, 2021
  • Poliomyelitis - Pipeline by GlaxoSmithKline Plc, 2021
  • Poliomyelitis - Pipeline by Grifols SA, 2021
  • Poliomyelitis - Pipeline by Helix Biogen Institute, 2021
  • Poliomyelitis - Pipeline by Johnson & Johnson, 2021
  • Poliomyelitis - Pipeline by KM Biologics Co Ltd, 2021
  • Poliomyelitis - Pipeline by LG Chem Ltd, 2021
  • Poliomyelitis - Pipeline by Micron Biomedical Inc, 2021
  • Poliomyelitis - Pipeline by Nanolek LLC, 2021
  • Poliomyelitis - Pipeline by Panacea Biotec Ltd, 2021
  • Poliomyelitis - Pipeline by Serum Institute of India Pvt Ltd, 2021
  • Poliomyelitis - Pipeline by Shantha Biotechnics Pvt Ltd, 2021
  • Poliomyelitis - Pipeline by Statera BioPharma Inc, 2021
  • Poliomyelitis - Pipeline by Univercells SA, 2021
  • Poliomyelitis - Pipeline by Vaxxas Inc, 2021
  • Poliomyelitis - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2021
  • Poliomyelitis - Dormant Projects, 2021
  • Poliomyelitis - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Poliomyelitis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Drugs In Development, 2021, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.

Polio is a highly infectious disease caused by a virus. It invades the nervous system and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 7, 7, 3, 5 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 3, 4, 2, 3 and 1 molecules, respectively.

Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Poliomyelitis - Overview
  • Poliomyelitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Poliomyelitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Poliomyelitis - Companies Involved in Therapeutics Development
  • Poliomyelitis - Drug Profiles
  • Poliomyelitis - Dormant Projects
  • Poliomyelitis - Discontinued Products
  • Poliomyelitis - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q